EIGR Overview
Upcoming Projects (EIGR)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (EIGR)
-
Discussing the development landscape of treatments for Congenital Hyperinsulinism (CHI) specifically: CRN04777, RZ358, and Avexitide.
Tickers: CRNX, RZLT, EIGR
Executed On: Feb 22, 2022 at 11:00 AM EST -
Discussing therapies in development for HDV with a focus on Eiger's lonafarnib
Ticker: EIGR
Executed On: Jan 20, 2022 at 10:30 AM EST
Expired Projects (EIGR)
-
Discussing Eiger Bio’s Peginterferon Lambda (Lambda) and Lonafarnib (Ritonavir) in treating HDV (Hepatitis Delta Virus) Infection
Ticker: EIGR
Execute By: Jan 31, 2023
Upcoming & Overdue Catalysts (EIGR)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (EIGR)
-
Phase 2 data of Avexitide (Exendin 9-39) in Post-Bariatric Hypoglycemia (PBH) to be presented at ENDO March 25, 2019.
Ticker: EIGR
Occurred on: Mar 25, 2019 -
Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension expected to read out in Q1 2018
Ticker: EIGR
Occurred on: Jan 16, 2018 -
FDA Grants Orphan Designation to Eiger Bio's (EIGR) Exendin 9-39 in Hyperinsulinemic Hypoglycemia
Ticker: EIGR
Occurred on: Dec 12, 2016 -
Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension
Ticker: EIGR
Occurred on: Jul 18, 2016
Strategic Initiatives (EIGR)
